Patrick Weydt

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy
    Michael D Weiss
    University of Washington Medical Center, Seattle, WA 98195, USA
    Expert Opin Pharmacother 5:735-46. 2004
  2. ncbi request reprint The role of microglial cells in amyotrophic lateral sclerosis
    Patrick Weydt
    Department of Laboratory Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Phys Med Rehabil Clin N Am 16:1081-90, xi. 2005
  3. ncbi request reprint Assessing disease onset and progression in the SOD1 mouse model of ALS
    Patrick Weydt
    Department of Neurology, University of Washington, PO Box 356465, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Neuroreport 14:1051-4. 2003
  4. ncbi request reprint Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival
    Patrick Weydt
    Department of Neurology, University of Washington, Seattle, WA 98195, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 6:182-4. 2005
  5. ncbi request reprint Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice
    Anke Witting
    Department of Pharmacology, University of Washington, Seattle, WA, USA
    J Neurochem 89:1555-7. 2004
  6. ncbi request reprint Increased cytotoxic potential of microglia from ALS-transgenic mice
    Patrick Weydt
    Department of Neurology, University of Washington, Seattle, Washington 98195, USA
    Glia 48:179-82. 2004
  7. ncbi request reprint Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats
    Yiheng Xie
    Department of Neurology, School of Medicine, University of Washington, Seattle, WA 98195 6465, USA
    Neuroreport 15:2513-6. 2004
  8. ncbi request reprint Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study
    Gregory T Carter
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    Am J Hosp Palliat Care 22:55-9. 2005
  9. ncbi request reprint Medicinal cannabis: rational guidelines for dosing
    Gregory T Carter
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98531, USA
    IDrugs 7:464-70. 2004
  10. ncbi request reprint Skeletal muscle in amyotrophic lateral sclerosis: emerging concepts and therapeutic implications
    Simone Abmayr
    Department of Neurology, University of Washington, 1959 NE Pacific Street Seattle, WA 98195, USA
    Phys Med Rehabil Clin N Am 16:1091-7, xi-xii. 2005

Detail Information

Publications18

  1. ncbi request reprint Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy
    Michael D Weiss
    University of Washington Medical Center, Seattle, WA 98195, USA
    Expert Opin Pharmacother 5:735-46. 2004
    ..Based on the available data, it is our opinion that combination drug therapies should be considered for future clinical trials...
  2. ncbi request reprint The role of microglial cells in amyotrophic lateral sclerosis
    Patrick Weydt
    Department of Laboratory Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Phys Med Rehabil Clin N Am 16:1081-90, xi. 2005
  3. ncbi request reprint Assessing disease onset and progression in the SOD1 mouse model of ALS
    Patrick Weydt
    Department of Neurology, University of Washington, PO Box 356465, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Neuroreport 14:1051-4. 2003
    ..We found that paw grip endurance is a sensitive and inexpensive alternative to the widely used rotarod test...
  4. ncbi request reprint Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival
    Patrick Weydt
    Department of Neurology, University of Washington, Seattle, WA 98195, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 6:182-4. 2005
    ..Further research is necessary to determine whether non-psychotropic cannabinoids might be useful in ameliorating symptoms in ALS...
  5. ncbi request reprint Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice
    Anke Witting
    Department of Pharmacology, University of Washington, Seattle, WA, USA
    J Neurochem 89:1555-7. 2004
    ..Our results show that chronic neurodegeneration induced by a genetic mutation increases endocannabinoid production possibly as part of an endogenous defense mechanism...
  6. ncbi request reprint Increased cytotoxic potential of microglia from ALS-transgenic mice
    Patrick Weydt
    Department of Neurology, University of Washington, Seattle, Washington 98195, USA
    Glia 48:179-82. 2004
    ..Neonatal microglia, however, showed no differences. Our findings suggest an increased cytotoxic potential of adult mtSOD1 microglia, which only becomes apparent after microglial activation...
  7. ncbi request reprint Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats
    Yiheng Xie
    Department of Neurology, School of Medicine, University of Washington, Seattle, WA 98195 6465, USA
    Neuroreport 15:2513-6. 2004
    ..We found that several pro-inflammatory mediators are up-regulated at asymptomatic and end-stages, whereas VEGF, a neuroprotective factor was down-regulated...
  8. ncbi request reprint Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study
    Gregory T Carter
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    Am J Hosp Palliat Care 22:55-9. 2005
    ..1 (SD 5.4), with p < 0.01. This pilot study suggests that modafinil is well-tolerated and may reduce symptoms of fatigue in ALS. Further blinded, controlled studies of modafinil in larger numbers of ALS patients are warranted...
  9. ncbi request reprint Medicinal cannabis: rational guidelines for dosing
    Gregory T Carter
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98531, USA
    IDrugs 7:464-70. 2004
    ..This paper will review the known chemistry and pharmacology of cannabis and, on that basis, discuss rational guidelines for dosing...
  10. ncbi request reprint Skeletal muscle in amyotrophic lateral sclerosis: emerging concepts and therapeutic implications
    Simone Abmayr
    Department of Neurology, University of Washington, 1959 NE Pacific Street Seattle, WA 98195, USA
    Phys Med Rehabil Clin N Am 16:1091-7, xi-xii. 2005
  11. ncbi request reprint Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Gregory T Carter
    Muscular Dystrophy Association Amyotrophic Lateral Sclerosis Center, University of Washington School of Medicine, Seattle, WA 98195, USA
    IDrugs 6:147-53. 2003
    ..We indicate current and future directions in research and clinical trials, and also argue that a logical next step for clinical trials in ALS should be combination drug treatment...
  12. ncbi request reprint Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis
    Patrick Weydt
    Department of Neurology, School of Medicine, University of Washington, Seattle, WA 98195 6465, USA
    Neuroreport 16:527-31. 2005
    ..A better understanding of neuroinflammation in motor neuron degeneration and amyotrophic lateral sclerosis disease progression promises to improve the rational design of greatly needed therapies...
  13. ncbi request reprint Cannabis: old medicine with new promise for neurological disorders
    Gregory T Carter
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle 98531, USA
    Curr Opin Investig Drugs 3:437-40. 2002
    ..This article reviews the emerging research on the physiological mechanisms of endogenous and exogenous cannabinoids in the context of neurological disease...
  14. ncbi request reprint Survey of cannabis use in patients with amyotrophic lateral sclerosis
    Dagmar Amtmann
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    Am J Hosp Palliat Care 21:95-104. 2004
    ..Cannabis was reported ineffective in reducing difficulties with speech and swallowing, and sexual dysfunction. The longest relief was reported for depression (approximately two to three hours)...
  15. ncbi request reprint Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis
    Patrick Weydt
    Department of Neurology, University of Washington School of Medicine, 1959 Northeast Pacific Avenue, Seattle, WA 98195, USA
    Curr Opin Investig Drugs 3:1720-4. 2002
    ..This article reviews the current research in this area and discusses theoretical and clinical ramifications of these recent findings...
  16. ncbi request reprint Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration
    Patrick Weydt
    Department of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA
    Cell Metab 4:349-62. 2006
    ..Finally, HD striatal neurons expressing exogenous PGC-1alpha were resistant to 3-nitropropionic acid treatment. Altered PGC-1alpha function may thus link transcription dysregulation and mitochondrial dysfunction in HD...
  17. ncbi request reprint Electrodiagnostic evaluation of hereditary motor and sensory neuropathies
    Gregory T Carter
    Department of Rehabilitation Medicine, University of Washington School of Medicine, 1959 Northeast Pacific Avenue, Seattle, WA 98195, USA
    Phys Med Rehabil Clin N Am 14:347-63, ix-x. 2003
    ..Nevertheless, there are exceptions. This article reviews the available literature and describes the electrodiagnostic approach to HMSN, detailing potential sources of error that can lead to misinterpretation of data...
  18. ncbi request reprint Targeting toxic proteins for turnover
    Albert R La Spada
    Nat Med 11:1052-3. 2005